SWK Holdings Corporation (SWKH)
| Market Cap | 247.20M |
| Revenue (ttm) | 57.91M |
| Net Income (ttm) | 26.02M |
| Shares Out | 12.83M |
| EPS (ttm) | 2.03 |
| PE Ratio | 9.49 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,762 |
| Open | 19.19 |
| Previous Close | 19.30 |
| Day's Range | 19.19 - 19.34 |
| 52-Week Range | 16.02 - 20.49 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | 24.99 (+29.8%) |
| Earnings Date | May 16, 2022 |
About SWKH
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately man...
Financial Performance
In 2021, SWK Holdings's revenue was $56.16 million, an increase of 52.96% compared to the previous year's $36.71 million. Earnings were $25.93 million, an increase of 398.44%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for SWKH stock is "Buy." The 12-month stock price forecast is 24.99, which is an increase of 29.75% from the latest price.
News
SWK Holdings Corporation Announces Filing of Form S-3 Shelf Registration Statement
Authorizes 10b5-1 Stock Repurchase Program DALLAS , May 19, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company cateri...
SWK Holdings Corporation Announces Financial Results for First Quarter 2022
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET Corporate Highlights During first quarter of 2022, completed two structured debt transactions deploying $18...
SWK Holdings Corporation to Report First Quarter 2022 Financial Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS , May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a l...
Enteris BioPharma to Exhibit at CPhI North America 2022
BOONTON, N.J. , May 4, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsid...
Enteris BioPharma Announces Acceptance of Two Abstracts for Presentation at ENDO 2022 Annual Conference
BOONTON, N.J. , April 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned sub...
Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologi...
Article describes unique features of Enteris' Peptelligence ® and ProPerma ® peptide and small molecule oral delivery technology BOONTON, N.J., April 4, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021
Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K.
AOTI Secures Major Expansion Funding from Leading Healthcare Financier
OCEANSIDE, Calif. , March 25, 2022 /PRNewswire/ -- Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today they have closed a signif...
SWK Holdings to Participate in Maxim's 2022 Virtual Growth Conference
DALLAS , March 23, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-sta...
Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufa...
BOONTON, N.J., March 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsi...
Enteris BioPharma to Participate in DCAT® Week 2022
BOONTON, N.J., March 2, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsi...
SWK Holdings Announces Reconstitution of Board of Directors with New Appointments
DALLAS, Feb. 16, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announ...
Enteris BioPharma Highlights Progress in Oral Feasibility Program
BOONTON, N.J., Feb. 15, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsi...
SWK HOLDINGS (SWKH) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating SWK Holdings Corporation For Potentia...
WILMINGTON, Del.--(BUSINESS WIRE)--Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations a...
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
DALLAS, Feb. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage ...
Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services
BOONTON, N.J., Jan. 10, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsi...
SWKH or AXP: Which Is the Better Value Stock Right Now?
SWKH vs. AXP: Which Stock Is the Better Value Option?
Special Committee Concludes Review of Non-Binding Proposal from Carlson Capital
DALLAS, Jan. 5, 2022 /PRNewswire/ --SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board of directors (the "Special Committe...
Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook
BOONTON, N.J., Jan. 5, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsid...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Sale of SWK H...
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SWK Holdings Corporation ("SWK" or the "Company") (NAS...
Enteris BioPharma to Participate in Biotech Showcase Virtual and BIO Partnering at JPM During "J.P. Morgan Week 2022"
BOONTON, N.J., Dec. 20, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsi...
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
DALLAS, Dec. 9, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announ...
Kaskela Law LLC Announces Stockholder Investigation of SWK Holdings Corporation (SWKH) and Encourages Investors to Co...
Philadelphia, Pennsylvania--(Newsfile Corp. - December 5, 2021) - Kaskela Law LLC announces that it is investigating SWK Holdings Corporation (NASDAQ: SWKH) ("SWK") on behalf of the company's shareholde...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Sale of SWK H...
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SWK Holdings Corporation ("SWK" or the "Company") (NASD...
SWK Holdings Confirms Receipt of Non-Binding Proposal from Carlson Capital L.P.
DALLAS, Nov. 24, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on November 23, 2021, it received a non-binding proposal from funds managed by Carls...